Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia

NCT03382639 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03382639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Completed
Start date
January 4, 2018
Completion date
January 12, 2021
Enrollment
256 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia